|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM142415227 |
| 003 |
DE-627 |
| 005 |
20231223024511.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0475.xml
|
| 035 |
|
|
|a (DE-627)NLM142415227
|
| 035 |
|
|
|a (NLM)14499247
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tacket, Carol O
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.10.2003
|
| 500 |
|
|
|a Date Revised 08.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Norwalk virus-like particles (VLPs), made from recombinant capsid protein, are a promising vaccine. Thirty-six healthy adult volunteers received 250 microg (n = 10), 500 microg (n = 10), or 2000 microg (n = 10) of orally administered VLP or placebo (n = 6). All vaccinees developed significant rises in IgA anti-VLP antibody-secreting cells. Ninety percent who received 250 microg developed rises in serum anti-VLP IgG; neither the rates of seroconversion nor geometric mean titers increased at the higher doses. About 30-40% of volunteers developed mucosal anti-VLP IgA. Lymphoproliferative responses and IFN-gamma production were observed transiently among those who received 250 microg or 500 microg but not 2000 microg of VLP. Studies to increase immunogenicity using a mucosal adjuvant are planned
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A, Secretory
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Vaccines, Synthetic
|2 NLM
|
| 650 |
|
7 |
|a Viral Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Sztein, Marcelo B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Losonsky, Genevieve A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wasserman, Steven S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Estes, Mary K
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 108(2003), 3 vom: 19. Sept., Seite 241-7
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:108
|g year:2003
|g number:3
|g day:19
|g month:09
|g pages:241-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 108
|j 2003
|e 3
|b 19
|c 09
|h 241-7
|